Financials data is unavailable for this security.
View more
Year on year Esperion Therapeutics Inc grew revenues 54.14% from 75.48m to 116.33m while net income improved from a loss of 233.66m to a smaller loss of 209.25m.
Gross margin | 81.82% |
---|---|
Net profit margin | -35.46% |
Operating margin | -17.38% |
Return on assets | -33.56% |
---|---|
Return on equity | -- |
Return on investment | -64.71% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Esperion Therapeutics Inc fell by 42.53m. Cash Flow from Financing totalled 50.46m or 43.38% of revenues. In addition the company used 135.49m for operations while cash from investing totalled 42.50m.
Cash flow per share | -0.6533 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -1.77 |
---|---|
Tangible book value per share | -1.77 |
More ▼
Balance sheet in USDView more
Current ratio | 1.97 |
---|---|
Quick ratio | 1.49 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼